Citations

Clear

1893 citation(s) found for "Wu, Kenneth".

PS01.045: ENDOSCOPIC NEGATIVE INTRACAVITARY PRESSURE (ENDO-NIP) TO MANAGE ESOPHAGEAL LEAK AND MEDIASTINAL ABSCESS COMPLICATED BY STROKE TREATED WITH TPA
Singh, Prabh G. , Bhangoo, Harangad S. , Meyer, Alyssa J. , Rizvi, Zaheer H., Buttar, Navtej , Wang, Kenneth , Singh, Prabh G

Mayo Clinic

Diseases of the Esophagus | September 16, 2018 | Volume: 31 | Issue: Supplement_1 | Pages: 62-63

10.1093/dote/doy089.ps01.045 Get It

Abstract Background Post-surgical complications such as leaks are the source of considerable morbidity and mortality. Success of conservative interventions is highly variable. Recurrence after surgical repair is also not uncommon. Our aim was to develop novel endoscopic strategies to maximize negative intracavitary pressure to manage leaks in cases where conventional management either failed or were not feasible. Methods We have used transluminal locking loop drains with low intermittent suction in the management of non-healing leaks in various areas. An example presented here illustrates this concept where a 68-year-old male patient underwent paraesophageal hernia repair with Nissen fundoplication. Patient presented 3 weeks later with fistula leading to a 13 cm meditational abscess. Patient developed right hemiparesis requiring tissue plasminogen activator (tPA). Post-tPA patient developed hemoptysis and hematemesis requiring emergency intubation. The defect in the esophagus was 6–8 mm. Endoscopic repair with stitching or clipping would have left a large undrained cavity with a potential to expand. Endoscopic repair with transcutaneous drain placement was challenging due to recent tPA and a difficult location. Moreover there was potential to develop esophago- pleural- broncho- cutaneous fistula. Endoscopic vacuum therapy was felt to be a suboptimal choice. Patient was high-risk surgical candidate as it would have required radical surgery in the setting of tPA.Upper endoscopy was performed and the cavity was debrided. No direct communication with bronchopulmonary tree noted. A transnasal guidewire assisted 16 Fr, 60 cm locking loop drain was placed and connected to low intermittent suction that was switched to bulb based suction. Results The output from naso-cavity drain decreased nearly 100 cc per day in the first 5 days and the size reduced by 30, 50 and 80% by day 5, 9 and 12 respectively. Near complete elimination of the cavity was observed on day 15. Esophagogram showed complete resolution of the leak and computerized tomography revealed no residual cavity Conclusion Developing transluminal endoscopic strategies to maximize negative intracavitary pressure helps expedite the healing of resistant postsurgical leaks. This technique avoids the need for frequent drain changes that remains a challenge for vacuum therapy. Disclosure All authors have declared no conflicts of interest.
FA02.07: BARRIER STRUCTURE AND FUNCTION OF THE NEO-SQUAMOUS EPITHELIUM FOLLOWING SUCCESSFUL BARRETT’S ENDOTHERAPY IS IMPAIRED
Ravindran, Adharsh, Blevins, Christopher H. , Johnson, Michele L., Lansing, Ramona, Katzka, David A. , Iyer, P. K. R., Wang, Kenneth , Iyer, Prasad

Mayo Clinic

Diseases of the Esophagus | September 14, 2018 | Volume: 31 | Issue: Supplement_1 | Pages: 5-5

10.1093/dote/doy089.fa02.07 Get It

Abstract Background The neo-squamous epithelium that replaces columnar epithelium after successful endoscopic ablation of Barrett's esophagus (BE) has not been fully characterized in regard to its structural and functional integrity. Intercellular space is a surrogate marker for epithelial structural integrity and mucosal impedance (MI) is a surrogate for transepithelial resistance and thus epithelial functional integrity. Impairment of the structural and functional integrity may influence recurrence following successful ablation. We aimed to measure the esophageal epithelial intercellular space diameter and MI in the neo-squamous and normal squamous epithelium of patients who underwent successful radiofrequency ablation for dysplastic BE. Methods Forty patients with complete remission of intestinal metaplasia (CRIM) (defined as two negative surveillance endoscopies for intestinal metaplasia) were prospectively recruited. Patients were excluded if they had endoscopic evidence of esophagitis. MI measurements were taken at 1 cm above the GE junction and 2 cm above the prior BE segment (targeting uninvolved squamous epithelium), using a novel through the scope MI probe. Endoscopic biopsies were also taken at these corresponding sites to assess intercellular space diameter using transmission electron microscopy (TEM) using standard techniques. Results 80% of patients were male with a mean age of 69 years. Mean follow since achieving CRIM was 30 months. 39 patients underwent RFA for dysplasia. The mean intercellular space diameter was higher in the neo-squamous epithelium (1.01 μm) when compared to the untreated native squamous epithelium (0.96 μm) [Difference of 0.056 μm, 95% CI of -0.036 to 0.148, P = 0.228]. The mean MI was significantly lower in the neosquamous epithelium (4001.3 Ω) when compared to the untreated native epithelium (5168.1 Ω) [Difference of 1166.7 Ω, 95% CI 418.8 to 1914.6, P = 0.003]. Conclusion Neo-squamous epithelium that replaces BE epithelium following successful endoscopic therapy for BE appears to be functionally and likely structurally deficient with regards to acid reflux barrier function, when compared to native squamous esophageal epithelium. This impairment may be associated with recurrence following successful ablation. Disclosure All authors have declared no conflicts of interest.
Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA 2 DS 2 ‐VASc Scores: Findings From the ORBIT‐AF I and II Registries
Kim, Sunghee , Go, Alan S. , Kowey, Peter R. , Mahaffey, Kenneth W. , Singer, Daniel E. , Thomas, Laine , Blanco, Rosalia , Piccini, Jonathan P. , Investigators, the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Patients and, Jackson, Larry R. , Fonarow, Gregg C. , Freeman, James V. , Gersh, Bernard J. , Hylek, Elaine M. , Peterson, Eric D. , Investigators, the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Patients and

Mayo Clinic

Journal of the American Heart Association | September 14, 2018 | Volume: 7 | Issue: 16 | Pages: No page available

10.1161/jaha.118.008764 | PMID 30369317 Get It

Background Current American College of Cardiology/American Heart Association guidelines suggest that for patients with atrial fibrillation who are at low risk for stroke (CHA 2 DS 2 VASc=1) (or women with CHA 2 DS 2 VASc=2) a variety of treatment strategies may be considered. However, in clinical practice, patterns of treatment in these “low‐risk” patients are not well described. The objective of this analysis is to define thromboembolic event rates and to describe treatment patterns in patients with low‐risk CHA 2 DS 2 VASc scores. Methods and Results We compared characteristics, treatment strategies, and outcomes among patients with a CHA 2 DS 2 VASc=0, CHA 2 DS 2 VASc=1, females with a CHA 2 DS 2 VASc=2, and CHA 2 DS 2 VASc ≥2 in ORBIT‐AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) I & II. Compared with CHA 2 DS 2 VASc ≥2 patients (84.2%), those with a CHA 2 DS 2 VASc=0 (60.3%), 1 (69.9%), and females with a CHA 2 DS 2 VASc score=2 (72.4%) were significantly less often treated with oral anticoagulation ( P <0.0001). Stroke rates were low overall and ranged from 0 per 100 patient‐years in those with CHA 2 DS 2 VASc=0, 0.8 (95% confidence interval [CI] [0.5–1.2]) in those with CHA 2 DS 2 VASc=1, 0.8 (95% CI [0.4–1.6]) in females with a CHA 2 DS 2 VASc score=2, and 1.7 (95% CI [1.6–1.9]) in CHA 2 DS 2 VASc ≥2. All‐cause mortality (per 100 patient‐years) was highest in females with a CHA 2 DS 2 VASc score=2 (1.4) (95% CI [0.8–2.3]), compared with patients with a CHA 2 DS 2 VASc=0 (0.2) (95% CI [0.1–1.0]), and CHA 2 DS 2 VASc=1 (1.0) (95% CI [0.7–1.4]), but lower than patients with a CHA 2 DS 2 VASc ≥2 (5.7) (95% CI [5.4–6.0]). Conclusion The majority of CHA 2 DS 2 VASc=0‐1 patients are treated with oral anticoagulation. In addition, the absolute risks of death and stroke/transient ischemic attack were low among both male and females CHA 2 DS 2 VASc=0‐1 as well as among females with a CHA 2 DS 2 VASc score=2. Clinical Trial Registration URL: http://www.clinicaltrials.gov . Unique identifier: NCT01701817.
FA02.06: VOLUMETRIC LASER ENDOMICROSCOPY GLAND QUANTIFICATION CAN GUIDE EN-BLOC RESECTION IN DYSPLASTIC BARRETT’S ESOPHAGUS
Kamboj, Amrit K. , Sawas, Tarek , Lutzke, Lori S., Kahn, Allon , Wang, Kenneth , Leggett, Cadman L.

Mayo Clinic

Diseases of the Esophagus | September 14, 2018 | Volume: 31 | Issue: Supplement_1 | Pages: 4-5

10.1093/dote/doy089.fa02.06 Get It

Abstract Background Endoscopic mucosal resection (EMR) can be performed en-bloc in Barrett's esophagus (BE) lesions that are ≤2 cm in size. The true size of a BE lesion may be underestimated under white light endoscopy, limiting the rate of en-bloc resection. Volumetric laser endomicroscopy (VLE) provides high-resolution cross-sectional imaging of BE. A greater number of VLE glands are associated with BE dysplasia and may help predict lesion size. The aim of this study was to determine the association between VLE gland count and outcome of resection. Methods EMR specimens from patients with a history of dysplastic BE were imaged with VLE. EMRs performed on BE lesions ≤2cm in size with intent at en-bloc resection were included. Manual quantification of epithelial glands was performed in blinded fashion. Image visualization enhancement software was used to quantify the surface area occupied by epithelial glands on en-face VLE. Histologic en-bloc (R0) and incomplete (R1) resection of the targeted lesion was defined by the absence and presence of dysplasia and/or cancer at the specimen margins respectively. Results The study sample consisted of 37 EMRs from 31 patients. The mean (SD) size of EMRs was 1.04 (0.37) cm. Pathology showed low-grade dysplasia (N = 12), high-grade dysplasia (N = 19), and intramucosal cancer (N = 6). The en-bloc resection rate was 37.8% (R0: N = 14; R1: N = 23). The mean (SD) number of epithelial glands was 13.0 (6.7) and 28.8 (23.9) for R0 and R1 specimens, respectively, with a statistically significant mean difference of 15.8 glands (95% CI: 2–29, P = 0.02) between the two groups. A gland count of 28 or higher per EMR specimen predicted R1 with 100% sensitivity and 39% specificity (ROC: 0.69). The mean (SD) surface area occupied by epithelial glands in R0 and R1 specimens was 0.98 (1.1) mm2 and 2.3 (2.4) mm2, respectively. There was strong correlation between manual gland counts and epithelial gland surface area (R2: 0.81, P < 0.001). Conclusion A higher number of VLE glands in EMR specimens is associated with a lower en-bloc resection rate suggesting that white-light endoscopy underestimates lesion size and that VLE may have a potential role in lesion margin assessment. Disclosure All authors have declared no conflicts of interest.
Prospective registry of multiplex testing (PROMPT): A web-based platform to assess cancer risk of genetic variants.
Walsh, Michael F. , Gaddam, Pragna, DiGiovanni, Laura , Dolinsky, Jill S. , Klein, Rachel , Lincoln, Stephen E. , Allen, Brian, Leighton, Justin, Strom, Charles M. , Ranger-Miller, Vanessa, Offit, Kenneth , Balmañà, Judith , Sittler, Taylor , Brown, Kyle, Garber, Judy E. , Couch, Fergus J. , Domchek, Susan M. , Robson, Mark E.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 1518-1518

10.1200/jco.2016.34.15_suppl.1518 Get It

CheckMate 436: A phase 1-2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas.
Carson, Kenneth R. , Shustov, Andrei R., Moskowitz, Alison J. , Campbell, Mary S., Salles, Gilles , Masood, Aisha, Ansell, Stephen M. , Salles, Gilles A , Barr, Paul M. , Brody, Joshua , Kline, Justin Paul , Savage, Kerry J. , Kuruvilla, John , Zinzani, Pier Luigi

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: TPS7577-TPS7577

10.1200/jco.2017.35.15_suppl.tps7577 Get It

TPS7577 Background: Nivolumab (nivo) is a PD-1 immune checkpoint inhibitor that augments T-cell activation and host anti-tumor responses. PD-1 blockade has shown promise in B- and T-cell non-Hodgkin lymphoma (NHL),1 but many patients (pts) with NHL do not respond or progress after response. Combination therapy using anti-tumor agents with complementary mechanisms of action and low immunosuppressive impact may result in more frequent and durable responses. Brentuximab vedotin (BV) is an anti-CD30 antibody–drug conjugate that induces cell cycle arrest and apoptosis, with activity in a range of NHL tumors.2,3 Tumor cells undergoing BV-induced apoptosis have shown subsequent immune-mediated anti-tumor cytotoxicity.4 Therefore, nivo and BV may synergize if combined for relapsed/refractory (RR) NHL. Methods: CheckMate 436 (NCT02581631) is a phase 1–2, open-label, international, single-arm study evaluating nivo + BV for CD30-expressing RR NHL (study start: Dec 2015) in pts with RR diffuse large B-cell lymphoma, peripheral T-cell lymphoma (excluding anaplastic large cell lymphoma), and cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome); cohorts with primary mediastinal B-cell lymphoma (PMBL) and mediastinal gray zone lymphoma were made eligible in Sept 2016. Pts with PMBL must be aged ≥15 y (≥18 y for other histologies). All pts must have CD30-expressing disease, defined by CD30 on ≥1% of tumor cells or tumor-infiltrating lymphocytes by immunohistochemistry. In the phase 1 component, 6 pts will receive nivo and BV until disease progression or unacceptable toxicity. In the phase 2 component, ~130 more pts across the 5 histologies will be enrolled and treated at the recommended dose. Primary endpoints: safety, tolerability, and investigator-assessed objective response rate; secondary endpoints: duration of response and complete response (CR), CR rate, and progression-free and overall survival. Accrual is ongoing. References: 1. Lesokhin A et al. JCO 2016;34:2698–704 2. Jacobsen E et al. Blood 2015;125:1394–402 3. Horwitz S et al. Blood 2014;123:3095–100 4. Gardai S et al. Cancer Res 2015;75(15 Suppl):2469 [abstract]. Clinical trial information: NCT02581631.
Identification of genetic test results with conflicting interpretations in prospective registry of multiplex testing (PROMPT).
DiGiovanni, Laura , Gaddam, Pragna, Walsh, Michael F. , Offit, Kenneth , Balmañà, Judith , Garber, Judy E. , Couch, Fergus J. , Robson, Mark E. , Domchek, Susan M.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 1510-1510

10.1200/jco.2016.34.15_suppl.1510 Get It

The origin of animals as microbial host volumes in nutrient-limited seas
Kaçar, Betül , Som, Sanjoy M. , NA, Adam, Zachary R. , Lynch, Kennda , Walther-António, Marina , Williford, Kenneth H. , NA

Mayo Clinic

No container title available | September 5, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7287/peerj.preprints.27173v1 Get It

The microbe-stuffed gut, rather than the genome, represents the most dynamic gene reservoir within complex, multicellular metazoa (animals). Microbes are known to confer increased metabolic efficiency, increased nutrient recovery, and tolerance of ocean acidity to basal taxa such as sponges, arguably the extant taxa most comparable to the first metazoan. We hypothesize that metazoan origins may be rooted in the capability to compartmentalize, metabolize, and exchange genetic material with a modulated microbiome. We present evidence that the most parsimonious adaptive response of clonal eukaryotic colonies experiencing oligotrophic (nutrient-limited) conditions that accompanied Neoproterozoic glaciation events, which were broadly contemporaneous with metazoan origins, is to evolve a morphological volume to harbor a densified microbiome. Dense microbial communities housed within a cavity would increase instances of horizontal gene transfer between microorganisms and host, accelerating evolutionary innovation at the genetic and epigenetic levels for the holobiont. The accelerated tempo of genetic exchange would continue until the host’s metabolic and reproductive cells became spatially and temporally segregated from one another, at which point the process is effectively suppressed with the emergence of specialized gut and reproductive tissues. This framework may lead to new, testable hypotheses regarding metazoan evolution on Earth and a more tractable means of estimating the pervasiveness of complex, multicellular animal-like life with convergent morphologies on other planets.